Alpha Tau (NASDAQ: DRTSW) treats first patient in U.S. pancreatic cancer trial

Rhea-AI Filing Summary

Alpha Tau Medical Ltd. furnished a Form 6-K to provide investors with a press release dated September 2, 2025. The release, attached as Exhibit 99.1, announces that Alpha Tau successfully treated the first patient in its U.S. multi-center pancreatic cancer clinical trial.

The Form 6-K specifies that the information, including the exhibit, is furnished rather than filed under U.S. securities laws, which affects how it is incorporated into other regulatory documents.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO SECTION 13A-16 OR 15D-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2025

Commission File Number: 001-41316

Alpha Tau Medical Ltd.

(Exact Name of Registrant as Specified in Its Charter)

Kiryat HaMada St. 5

Jerusalem, Israel 9777605

+972 (3) 577-4115

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  ☒             Form 40-F  ☐

CONTENTS

On September 2, 2025, Alpha Tau Medical Ltd. (the “Company”) issued a press release titled “Alpha Tau Successfully Treats First Patient in its U.S. Multi-Center Pancreatic Cancer Clinical Trial.” A copy of this press release is attached to this Form 6-K as Exhibit 99.1.

The information in this Report on Form 6-K, including in Exhibit 99.1 attached hereto is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.

1  

EXHIBIT INDEX

Exhibit No.		Description
99.1		Press release dated September 2, 2025.

2  

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Alpha Tau Medical Ltd.
Date: September 2, 2025	By:	/s/ Uzi Sofer
		Uzi Sofer
		Chief Executive Officer

3

FAQ

What did Alpha Tau Medical Ltd. (DRTSW) report in this Form 6-K?

Alpha Tau Medical Ltd. furnished a Form 6-K to share a press release announcing successful treatment of the first patient in its U.S. multi-center pancreatic cancer clinical trial, dated September 2, 2025, which is attached as Exhibit 99.1.

What milestone did Alpha Tau (DRTSW) disclose for its pancreatic cancer clinical trial?

Alpha Tau disclosed that it has successfully treated the first patient in its U.S. multi-center pancreatic cancer clinical trial. This information is contained in a press release dated September 2, 2025, which is furnished as Exhibit 99.1 to the Form 6-K.

Is the Alpha Tau (DRTSW) pancreatic cancer trial information considered filed with the SEC?

The Form 6-K states that the information, including Exhibit 99.1, is being furnished rather than filed under the Exchange Act. This means it is not automatically subject to Section 18 liabilities or incorporated into other filings unless specifically referenced.

What exhibit is included with Alpha Tau Medical Ltd.’s (DRTSW) September 2025 Form 6-K?

The Form 6-K includes one exhibit, numbered 99.1, which is a press release dated September 2, 2025. That press release announces Alpha Tau’s successful treatment of the first patient in its U.S. multi-center pancreatic cancer clinical trial.

Why did Alpha Tau Medical Ltd. (DRTSW) issue a press release on September 2, 2025?

Alpha Tau issued the press release to announce that it successfully treated the first patient in its U.S. multi-center pancreatic cancer clinical trial. This press release is attached to the Form 6-K as Exhibit 99.1 for investors and regulators.